Home
overview
In our 3rd in a series of Diagnostics Conferences, SMi will be looking to bring together the leading experts from the pharmaceutical and diagnostics industry to determine the progress made in realising the potential of Point of care Diagnostics methods and test.

The POC market for diagnostic tests in the United States is increasing at a phenomenal compounded annual growth rate, and in many parts of the world market is growing at comparable rates, with Germany as the leader in Europe and high rates of growth in rest of the world including Asia and Japan. Point-of-care diagnostic technology includes portable, instrument-based diagnostic devices used in near-patient hospital and alternate care settings. In 2001, U.S. sales of point-of-care diagnostic devices totalled approximately $2.8 billion and are expected to increase. The Point of Care Diagnostic products segments are poised for a major new phase of growth fuelled by the availability of new technology platforms an the demand for more efficient medical service.

The conference will include presentations from market leaders, specialist companies and renowned experts to talk about the competitive outlook & market strategies. It also covers specific at point of care testing areas such as glucose monitoring, pregnancy testing, hepatitis, drug abuse, infectious diseases and HIV.

Including valuable contributions from:
· Dr Thomas Mann, Head of National Implementation Team, Department of Health
· Prof Christopher Price, Vice President, Global Clinical Research, Diagnostics Division, Bayer HealthCare
· Dr Michael Pugia, Director, New Products, Urine Chemistry, Diagnostics Division, Bayer HealthCare
· Andy Bufton, Director, External & Regulatory Affairs, Abbott Diagnostics
· Roger Kirkbride, Head, Healthcare Development, Boots
· Dr Ian Barnes, Head of Pathology, Leeds Teaching Hospitals NHS Trust
· Svein Lien, Chief Executive Officer, Axis-Shield
· Clint Severson, Chairman, President & Chief Executive Officer, Abaxis
· S Wayne Kay, President & Chief Executive Officer, Quidel

Programme highlights that will be addressed at the Conference:
· POINT OF CARE TESTING FOR HIV, CANCER, DRUGS OF ABUSE, INFECTIOUS DISEASE: Learn about innovative technology platforms and improvements to existing solutions
· HEALTH OUTCOMES FROM POINT OF CARE TESTING: What are they and how do they affect the health service?
· OVER THE COUNTER DIAGNOSTIC PRODUCTS: Analyse global market trends and assess healthcare cost control
· PRICING AND REIMBURSEMENT: How is point of care testing funded? – perspectives from government, hospital and industry
· DECENTRALISATION OF PATIENT TESTING: Consider cost analysis for testing point of care vs central lab

Conference programme

8:30 Registration and Coffee

9:00 Chairperson’s Opening Remarks

Doris-Ann Williams

Doris-Ann Williams, Director General, British In Vitro Diagnostics Association (BIVDA)

9:10 KEYNOTE ADDRESS

Bill Cunningham

Bill Cunningham, Managing Director, CDx

  • Global point of care testing market
  • Sector consolidation
  • Diagnostic testing growth trends
  • Acquisition, license agreements, internal developments and partnerships
  • The move to complete product portfolio
  • Does market penetration in point of care increase?
  • 9:40 DRUGS OF ABUSE

    Gerald Moore

    Gerald Moore, President & Chief Executive Officer, American Bio Medica Corporation

  • Examine the technology trends in drugs of abuse screening
  • Technological advances are big in drugs of abuse screening
  • How is the market set to grow?
  • Interacting with healthcare professionals
  • Gain an insight into how the market will develop
  • 10:20 ONSITE TESTING SYSTEMS FOR DRUGS OF ABUSE IN ORAL FLUID

    Dr Christopher Hand

    Dr Christopher Hand, Managing Director, Cozart Bioscience

  • Integrated immunoassay, software and portable instrument test system
  • Ability to test for up to 20 substances from a single oral fluid specimen
  • Healthcare, criminal justice and workplace testing application
  • 11:00 Morning Coffee

    11:20 URINALYSIS TESTING

    Dr Michael Pugia

    Dr Michael Pugia, Director, New Products, Urine Chemistry, Diagnostics Division, Bayer HealthCare

  • Impact of advances in instrumentation and data management on utility and value of urinalysis testing
  • New benefits of urinalysis reagents in kidney disease, diabetes and infection control
  • Creatinine ratios as the replacement for the 24 hour urine collection
  • Urinary inflammation markers serving as non-invasive measures of general infection
  • Algorithms for better disease management through point of care testing
  • Technology trends in miniaturisation and system consolidation for the future
  • 12:00 CARDIOVASCULAR DIAGNOSTICS

    Warren Pinckert II

    Warren Pinckert II, President & Chief Executive Officer, Cholestech

  • What are the specific areas of cardiovascular risk assessment and patient monitoring in the physician’s office?
  • What products are on the market and how are they performing?
  • Gain an understanding of the current market trend and how it is set to develop
  • What are the hot topics of research and when will they emerge from R&D?
  • Where do future opportunities lie?
  • 12:40 Networking Lunch

    14:00 CASE STUDY: SPECTRAL

    Dr Paul Walker

    Dr Paul Walker, President & Chief Executive Officer, Spectral Diagnostics

  • Diagnostics – novel analytes
  • Clinical studies – developing a body of evidence
  • Establishing critical relationships with clinical reference laboratories and “Big” diagnostic companies
  • Link to therapy
  • Promotion to doctors, consumers, clinical reference laboratories and health plans
  • 14:40 INFECTIOUS DISEASE

    S Wayne Kay

    S Wayne Kay, President & Chief Executive Officer, Quidel

  • Examine the technology trends in infectious disease testing
  • What is the current market size and how is it set to grow?
  • Prominent technologies in infectious disease testing
  • Is the future in point of care or laboratory testing?
  • Gain an insight into how the market will develop
  • 15:20 Afternoon Tea

    15:40 HIV TESTING

    Bill Bruckner

    Bill Bruckner, Vice President of Strategic Marketing, OraSure Technologies

  • Brief outline of the technology
  • How this test helps to detect the virus in a cost efficient way
  • The growth of the market
  • The industry prospects
  • Reaching the developing world
  • Future markets
  • 16:20 THE OVER-THE-COUNTER DIAGNOSTIC PRODUCT MARKET

    Roger Kirkbride

    Roger Kirkbride, Head, Healthcare Development, Boots

  • What does the global OTC diagnostic market look like?
  • Paradigms for critical care and near patient testing
  • Trends in OTC testing and reimbursement
  • Growth of at home testing
  • Issues in computer assisted data analysis
  • Healthcare cost control
  • 17:00 Chairperson’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairperson's Opening Remarks

    S Wayne Kay

    S Wayne Kay, President & Chief Executive Officer, Quidel

    9:10 HEALTH OUTCOMES FROM POINT OF CARE TESTING

    Prof Christopher Price

    Prof Christopher Price, Vice President, Global Clinical Research, Diagnostics Division, Bayer HealthCare

  • An introduction to evidence based medicine and outcomes studies
  • Examples of clinical outcomes from POCT
  • Examples of economic outcomes from POCT
  • How POCT changes clinical practice
  • Challenges in changing clinical practice
  • How POCT complements changes in healthcare delivery
  • 9:40 PRICING AND REIMBURSEMENT

    Dr Thomas Mann

    Dr Thomas Mann, Head of National Implementation Team, Department of Health

    10:20 POCT FROM AN NHS PATHOLOGY PROVIDER PERSPECTIVE

    Dr Ian Barnes

    Dr Ian Barnes, Head of Pathology, Leeds Teaching Hospitals NHS Trust

  • Pathology modernisation agenda
  • Planning and configuration of services
  • Pricing and reimbursement of POCT
  • Does the pathology lab have a role?
  • Who defines the need for POCT?
  • 11:00 Morning Coffee

    11:20 DECENTRALISATION OF PATIENT TESTING

    Clint Severson

    Clint Severson , Chairman, President & Chief Executive Officer, Abaxis

  • The technologies involved
  • Market analysis: the leading suppliers
  • Cost pressures and perceived barriers
  • Moderators of growth
  • Importance and benefits of in-office testing
  • Attitudes of critical care nurses, physicians and doctors
  • 12:00 IMMUNODIAGNOSTICS AT POINT OF CARE LABORATORIES

    Olav Steinnes

    Olav Steinnes, Managing Director, Axis-Shield

  • Point of care immunodiagnostics market today
  • Clinical and market trends
  • Opportunities for the industry
  • Afinion: a new point of care platform meeting the future demands in the point of care laboratory
  • 12:40 Networking Lunch

    14:00 THE EMERGENCE OF THERANOSTICS

    John Funkhouser

    John Funkhouser, President, Chief Exectutive Officer, Pharmanetics

  • Background on technology
  • POC advantages in clinical trials
  • Theranostic commercialisation concerns of big pharma
  • Rallying physician and patient support
  • Is theranostics adoption inevitable?
  • 14:40 IT CONNECTIVITY AND DATA MANAGEMENT

    Andrew Bufton

    Andrew Bufton, Director, External & Regulatory Affairs, Abbott Diagnostics

  • Delivering and archiving POCT data
  • POCT connectivity requires simple maintenance
  • The added value of connectivity to POCT
  • 15:20 Afternoon Tea

    15:40 ACCELERATING MARKET ADOPTION OF RAPID POC SOLUTIONS

    Bill Radvak

    Bill Radvak, President & Chief Executive Officer, Response Biomedical

  • The spectrum of medical and environmental POC applications
  • Challenges and opportunities commercialising POC systems
  • Need and benefits of private sector collaborations
  • Impacts of regulatory processes
  • The case for quantitative immunoassay testing in the home
  • Vision for rapid POC testing
  • 16:20 THE FUTURE MARKET FOR POINT OF CARE TESTING (POCT)

    Dr Michael Groves

    Dr Michael Groves, Vice President, International Sales & Marketing, i-STAT

  • The value proposition of POCT
  • Market opportunities and growth potential
  • Role of connectivity
  • Cost pressures and perceived barriers
  • Future goals
  • 17:00 Chairperson’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.